Lit M Tablet contains Levocetirizine 5 mg and Montelukast 10 mg, combining an antihistamine and a leukotriene receptor antagonist to provide effective relief from allergic conditions. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, reducing symptoms such as sneezing, rhinorrhea, nasal congestion, and itching associated with allergic rhinitis and chronic urticaria. Montelukast acts by blocking leukotriene D4 receptors in the respiratory tract, thereby preventing bronchoconstriction, inflammation, and mucus production commonly observed in asthma and allergic rhinitis. The synergistic action of these agents offers comprehensive management of allergic symptoms, improving patient comfort and respiratory function. Lit M Tablet is indicated for the treatment of seasonal and perennial allergic rhinitis, chronic idiopathic urticaria, and as an adjunct therapy in asthma management to reduce airway inflammation and bronchospasm. It is generally well tolerated, with a low incidence of adverse effects such as headache, fatigue, and gastrointestinal disturbances. Caution is advised in patients with hepatic impairment and those with a history of neuropsychiatric events. Dosage and administration should be as prescribed by a healthcare professional, considering individual patient needs and clinical response.